secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029010
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025
--------------------------------------------------------------------------------

- Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.
- Cash and marketable securities $754.4M as of Dec 31, 2024; sufficient to fund operations into 2027.
- Phase 3 X-TOLE2/3 azetukalner FOS topline data expected H2 2025; Phase 3 MDD and bipolar depression trials advancing.
- CFO Sherry Aulin resigns effective June 30, 2025, for personal reasons; will advise through Aug 31, 2025.
- Neurocrine collaboration milestone triggers $7.5M payment; Phase 1 study of Nav1.2/1.6 inhibitor initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/0000950170-25-029010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/xene-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer